| Assessment Status |
Rapid Review Complete |
| HTA ID |
26045 |
| Drug |
Tarlatamab |
| Brand |
Imdylltra® |
| Indication |
Tarlatamab (Imdylltra®) is indicated as monotherapy for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) who require systemic therapy following disease progression on or after 1L treatment with platinum-based chemotherapy. |
| Rapid review commissioned |
11/09/2026 |
| Rapid review completed |
08/10/2026 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tarlatamab (Imdylltra®) compared with the current standard of care. |
